R
Ross C. Donehower
Researcher at Johns Hopkins University
Publications - 233
Citations - 32588
Ross C. Donehower is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Pharmacokinetics & Chemotherapy. The author has an hindex of 72, co-authored 229 publications receiving 28457 citations. Previous affiliations of Ross C. Donehower include Johns Hopkins University School of Medicine & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Phase I trial of bortezomib (PS-341) in combination with docetaxel in patients with advanced solid tumors.
Wells A. Messersmith,Sharyn D. Baker,K. Dinh,Lance K. Lassiter,R. A. Akdamar,John J. Wright,Ross C. Donehower,Michael A. Carducci,Deborah K. Armstrong +8 more
TL;DR: Bortezomib (PS-341), a first-in-class dipeptidyl boronic acid, is an inhibitor of the 26S proteasome, an ATP-dependent multicatalytic protease central to the ubiquitin-proteasome d...
Journal ArticleDOI
Phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis retinoic acid in patients with advanced solid tumors
Roberto Pili,Michelle A. Rudek,Soner Altiok,David Z. Qian,Ming Zhao,Ross C. Donehower,A. Anderson,M. Halter,H. McFarland,James A. Zwiebel,Michael A. Carducci +10 more
TL;DR: Combination of MS- 275 with CRA is reasonably well tolerated and 4 mg/m2 is the Phase II recommended dose for MS-275 in combination with CRA, and tumor response and PD data suggest clinical and biological activity for this combination strategy.
Journal ArticleDOI
Phase 2 study of programmed death-1 antibody (anti-PD-1, MK-3475) in patients with microsatellite unstable (MSI) tumors.
Dung T. Le,Nilofer S. Azad,Daniel A. Laheru,Ilene Browner,Hao Wang,Jennifer N. Uram,Holly Kemberling,Lei Zheng,Robert Iannone,Evan J. Friedman,Amy Meister,Ross C. Donehower,Ana De Jesus-Acosta,Luis A. Diaz +13 more
TL;DR: The treatment benefit and evaluation of MSI as a predictive marker of response to anti-PD-1 blockade are established and MK-3475 is a humanized monoclonal IgG4 antibody against PD-1 and is showing activity in multiple tumor types.
Journal ArticleDOI
The role of plasma level monitoring in cancer chemotherapy
Journal ArticleDOI
A phase I dose-escalation study of INCB028060, an inhibitor of c-MET receptor tyrosine kinase, in patients with advanced solid tumors.
Ross C. Donehower,A. Scardina,M. Hill,J. D. Bowman,Robert C. Newton,Xuesong Mike Liu,Peggy Scherle,Qiang Wang,S. Diamond,J. Boer,F. C. Lee,T. Gau,H. A. Burris,Johanna C. Bendell,Siân Jones,J. R. Infante +15 more
TL;DR: Toxicity has been manageable with INCB028060, the PK profile is favorable and supports exploration of a BID schedule, and dose-dependent decreases in phospho-c-MET are promising.